Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers

被引:25
作者
DeVane, CL
Markowitz, JS
Carson, SW
Boulton, DW
Gill, HS
Nahas, Z
Risch, SC
机构
[1] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA
[3] Univ N Carolina, Div Pharmacotherapy, Chapel Hill, NC USA
[4] ValueRx Inc, Minneapolis, MN USA
关键词
D O I
10.1097/00004714-200006000-00009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Six adults phenotyped as either extensive (N = 4) or poor (N = 2) metabolizers for cytochrome P450 (CYP) 2D6 were given a 10-mg oral dose of methylphenidate (MPH) on two separate occasions with and without quinidine, a potent CYP2D6 inhibitor. Quinidine had no significant effect on the pharmacokinetics of either MPH or ritalinic acid, its major metabolite, in either group of CYP2D6 metabolizers. These data suggest a lack of involvement of CYP2D6 in the metabolism of MPH. Drugs that are inhibitors of CYP2D6 when taken concurrently with MPH should not affect its plasma concentration.
引用
收藏
页码:347 / 349
页数:3
相关论文
共 15 条
[1]   SUSTAINED-RELEASE METHYLPHENIDATE - PHARMACOKINETIC STUDIES IN ADDH MALES [J].
BIRMAHER, B ;
GREENHILL, LL ;
COOPER, TB ;
FRIED, J ;
MAMINSKI, B .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1989, 28 (05) :768-772
[2]   The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans [J].
Capon, DA ;
Bochner, F ;
Kerry, N ;
Mikus, G ;
Danz, C ;
Somogyi, AA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (03) :295-307
[3]  
CHAN YPM, 1983, PEDIATRICS, V72, P56
[4]  
GREENHILL LL, 1991, RITALIN THORY PATIEN
[5]   CLINICAL CORRELATES OF METHYLPHENIDATE BLOOD-LEVELS [J].
GUALTIERI, CT ;
HICKS, RE ;
PATRICK, K ;
SCHROEDER, SR ;
BREESE, GR .
THERAPEUTIC DRUG MONITORING, 1984, 6 (04) :379-392
[6]  
HUNNINGHAKE D, 1970, Federation Proceedings, V29, P345
[7]   Drug interactions with psychostimulants [J].
Markowitz, JS ;
Morrison, SD ;
DeVane, CL .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1999, 14 (01) :1-18
[8]  
Patrick KM, 1987, PSYCHOPHARMACOLOGY 3, P1387
[9]  
Patrick KS, 1997, HUM PSYCHOPHARM CLIN, V12, P527, DOI 10.1002/(SICI)1099-1077(199711/12)12:6<527::AID-HUP932>3.0.CO
[10]  
2-U